WO1996021014A3 - Production et administration de retrovirus recombines a titre eleve - Google Patents

Production et administration de retrovirus recombines a titre eleve Download PDF

Info

Publication number
WO1996021014A3
WO1996021014A3 PCT/US1995/016852 US9516852W WO9621014A3 WO 1996021014 A3 WO1996021014 A3 WO 1996021014A3 US 9516852 W US9516852 W US 9516852W WO 9621014 A3 WO9621014 A3 WO 9621014A3
Authority
WO
WIPO (PCT)
Prior art keywords
administration
production
high titer
recombinant retroviruses
protein
Prior art date
Application number
PCT/US1995/016852
Other languages
English (en)
Other versions
WO1996021014A2 (fr
Inventor
Douglas J Jolly
Jack R Barber
Stephen M W Chang
James G Respess
John R Allen
Mordechai Bodner
Kimberly Chong
La Vega Dan De Jr
Nicholas J Depolo
David Chi-Tang Hsu
Carlos E Ibanez
Denice M Mittelstaedt
Charles E Prussak
Original Assignee
Viagene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viagene Inc filed Critical Viagene Inc
Priority to EP95944227A priority Critical patent/EP0796331A2/fr
Priority to AU46080/96A priority patent/AU4608096A/en
Publication of WO1996021014A2 publication Critical patent/WO1996021014A2/fr
Publication of WO1996021014A3 publication Critical patent/WO1996021014A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C12N9/1211—Thymidine kinase (2.7.1.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des procédés permettant d'obtenir des niveaux mesurables d'une protéine, d'une molécule d'acide nucléique ou d'un produit enzymatique dans un liquide biologique ou dans des cellules de l'homme, qui consistent à administrer à un individu une préparation rétrovirale recombiné possédant un titre sur des cellules HT1080 supérieur à 105 cfu/ml, ladite préparation étant capable de diriger l'expression d'une protéine, d'une molécule d'acide nucléique ou d'une enzyme générant un produit enzymatique, de façon à pouvoir obtenir dans le liquide biologique ou dans les cellules de l'homme des niveaux mesurables de la protéine, de la molécule d'acide nucléique ou du produit enzymatique.
PCT/US1995/016852 1994-12-30 1995-12-22 Production et administration de retrovirus recombines a titre eleve WO1996021014A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP95944227A EP0796331A2 (fr) 1994-12-30 1995-12-22 Production et administration de retrovirus recombines a titre eleve
AU46080/96A AU4608096A (en) 1994-12-30 1995-12-22 Production and administration of high titer recombinant retroviruses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36707194A 1994-12-30 1994-12-30
US08/367,071 1994-12-30

Publications (2)

Publication Number Publication Date
WO1996021014A2 WO1996021014A2 (fr) 1996-07-11
WO1996021014A3 true WO1996021014A3 (fr) 1996-09-26

Family

ID=23445824

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/016852 WO1996021014A2 (fr) 1994-12-30 1995-12-22 Production et administration de retrovirus recombines a titre eleve

Country Status (3)

Country Link
EP (1) EP0796331A2 (fr)
AU (1) AU4608096A (fr)
WO (1) WO1996021014A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
WO1998000542A2 (fr) * 1996-07-03 1998-01-08 Chiron Corporation Procedes d'administration d'excipients d'apport de genes recombines dans le traitement de l'hemophilie
WO1999007870A1 (fr) * 1997-08-11 1999-02-18 Chiron Corporation Methodes de modification genetique de lymphocytes t
JP2001514235A (ja) * 1997-09-02 2001-09-11 カイロン コーポレイション 遺伝子治療を利用して関節炎を処置するための組成物および方法
JP2003286199A (ja) * 2002-03-29 2003-10-07 Japan Science & Technology Corp タンパク質中空ナノ粒子を用いる肝臓疾患治療用薬剤
JP2003286198A (ja) * 2002-03-29 2003-10-07 Japan Science & Technology Corp 増殖因子等を提示するタンパク質中空ナノ粒子を用いる治療薬剤
EP1497437A4 (fr) 2002-05-01 2005-11-16 Cell Genesys Inc Particules de vecteur lentiviral resistantes a l'inactivation d'un complement

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994029440A1 (fr) * 1993-06-04 1994-12-22 The Regents Of The University Of California Production, concentration et transfert efficace de vecteurs retroviraux resultant de la formation de pseudotypes par la proteine g du virus de la stomatite vesiculeuse (vsv)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994029440A1 (fr) * 1993-06-04 1994-12-22 The Regents Of The University Of California Production, concentration et transfert efficace de vecteurs retroviraux resultant de la formation de pseudotypes par la proteine g du virus de la stomatite vesiculeuse (vsv)

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
D. JOLLY: "Viral vector systems for gene therapy", CANCER GENE THERAPY, vol. 1, no. 1, 1994, pages 51 - 64, XP002008051 *
D. MARKOWITZ ET AL.: "Retroviral gene transfer using safe and efficient packaging cell line", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 612, 1990, pages 407- - 414, XP002008048 *
D.M. BODINE ET AL.: "Development of a high titer retrovirus producer cell line and strategies for retrovirus-mediated gene transfer into rhesus monkey hematopoietic stem cells", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 612, 1990, pages 415 - 426, XP002008049 *
D.M. BODINE ET AL.: "Development of a high titer retrovirus producer cell line capable of gne transfer in rhesus monkey hematopoietic stem cells", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 87, 1990, pages 3738 - 3742, XP002008050 *
Y.-F. DAI ET AL.: "High efficient transfer and expression of human clotting factor IX cDNA in cultured human primary skin fibroblasts from hemophilia B patient by retroviral vectors", SCIENCE IN CHINA (SERIE B), vol. 35, no. 2, 1992, pages 183 - 193, XP002008052 *

Also Published As

Publication number Publication date
EP0796331A2 (fr) 1997-09-24
WO1996021014A2 (fr) 1996-07-11
AU4608096A (en) 1996-07-24

Similar Documents

Publication Publication Date Title
WO1998000541A3 (fr) Procedes d'administration de porteurs fournissant des genes recombinants pour le traitement d'une maladie chez l'homme
AU661901B2 (en) Protein C derivatives
CA2066204A1 (fr) Gene de la mucoviscidose
CA2180816A1 (fr) 6-dimethylaminomethyl-1-phenylcyclohexanes, principes actifs en pharmacie
CA2193337A1 (fr) Composes de type 1-phenyl-2-dimethylaminomethylcyclohexan-1-o1, ingredients pharmaceutiques actifs
ES2143641T3 (es) Expresion en superficie de una enzima en la terapia genica a base de promedicamentos.
EP0233013A3 (fr) Enzyme modifié
AU1951195A (en) Combinations of thrombolytically active proteins and anticoagulants, and uses thereof
CA2040815A1 (fr) Methode de stabilisation des enzymes
EP0147146A3 (fr) Accroissement de l'absorption percutanée d'un médicament
WO1996021014A3 (fr) Production et administration de retrovirus recombines a titre eleve
EP0744408A3 (fr) Protéine d'ob et son ADN
AU2157888A (en) Novel hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids
CA2154080A1 (fr) Nouveau type d'activite anticoagulante a cofacteur
AU3927189A (en) N-2,3-butadienyl tri- and tetraaminoalkane derivatives
WO1997026918A3 (fr) Therapie par promedicament a enzyme dirige par ligand
CA2175061A1 (fr) Muteines de fragments de beta-galactosidase ayant une activite accrue
MY103362A (en) Production of proteins in active forms
WO1997026867A3 (fr) Formes solides d'administration a liberation instantanee et leur procede de preparation
EP0680763A3 (fr) Préparation stable pour le traitement des anomalies de la coagulation du sang comprenant un facteur de coagulation activé et des vésicules lipidiques
WO1998024482A3 (fr) Utilisation de conjugues d'endothelines en therapie, nouveaux conjugues d'endothelines, agents les contenant, et leurs procedes de production
AU617330B2 (en) Human papillomavirus type 41, its DNA and the proteins encoded therefrom
WO1992002612A3 (fr) Variants d'activateur de plasminogene tissulaire avec espacement reduit
ATE103930T1 (de) Modifizierte proteine.
WO2001066709A3 (fr) Enzymes et utilisations les concernant

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 1995944227

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995944227

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref country code: US

Ref document number: 1997 1039

Date of ref document: 19971230

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1995944227

Country of ref document: EP